Dr. Reem

Assistant Professor

reem@cust.edu.pk

PROFILE SUMMARY

Dr. Reem earned her PhD in Pharmaceutical Chemistry in 2022 from Riphah International University, Pakistan, under the HEC Indigenous Scholarship Program. With over 10 years of experience in both teaching and the pharmaceutical industry, she has held various positions, including Lecturer, Assistant Professor, Associate Professor, Quality Control Manager and Acting Head of Department. Her research interests span neuroendocrinology, synthetic chemistry, bioinformatics, systems biology, and machine learning. Her work is particularly focused on gene identification using systems biology and machine learning approaches. She also specializes in 2D and 3D QSAR modeling of chemical compounds. Dr. Reem has co-supervised postgraduate research projects and holds a patent for a self-emulsifying drug delivery system. Currently, she is collaborating with the University of Florida, USA, on a project investigating senescence markers for age-related pain and disability in osteoarthritis.

QUALIFICATION
PhD	Pharmaceutical Chemistry	Riphah Institute of Pharmaceutical Sciences,Islamabad, Pakistan	2022
M.Phil	Reproductive Neuroendocrinology	Quaid-I-Azam University,Islamabad, Pakistan	2014

TEACHING EXPERIENCE
Assistant Professor	Capital University of Science and Technology (CUST), Islamabad	Since – 2024
Associate Professor	Iqra University, Islamabad H-9 Campus	2023 – 2024
Assistant Professor	Iqra University, Islamabad H-9 Campus	2022 – 2023

RESEARCH AREAS / INTERESTS
1.	Computational systems chemistry/biology
2.	Cancer Genomics
3.	Expressions and functional studies of Neurohormones

RESEARCH SUPERVISION
1.	PhD	Design, synthesis and pharmacological investigation of phenolic derivatives
2.	M.Phil	Virtual drug designing and in vitro evaluation of dihydropyrimidinones as potential antimicrobial agents
3.	M.Phil	Development and in vitro evaluation of edoxaban tosylate loaded self-emulsifying drug delivery system
4.	M.Phil	In silico, in vitro screening and preformulation studies of newly synthesized azoles derivatives as potential antimicrobial agents

SR.	JOURNAL PUBLICATIONS	YEAR
1	U. Ilyas, S. S. Jadoon, T. Ahmed, R. Altaf, A. Khan, A. Ahmad, Y. Rasool, S. M. Masaud, and Z. Khan, “Covid-19 and progress in therapeutic approaches: a narrative review,” Cukurova Medical Journal, vol. 49, no. 1, pp. 204–223, 2024.	2024
2	A. S. Sheikh, R. Altaf, H. Nadeem, M. T. Khan, and B. Murtaza, “Formation of morpholine-acetamide derivatives as potent anti-tumor drug candidates: Pharmacological evaluation and molecular docking studies,” Heliyon, vol. 9, no. 11, 2023.	2023
3	R. Altaf, U. Ilyas, A. Ma, and M. Shi, “Identification and validation of differentially expressed genes for targeted therapy in NSCLC using integrated bioinformatics analysis,” Frontiers in Oncology, vol. 13, p. 1206768, 2023.	2023
4	S. A. Azad, U. Ilyas, R. Altaf, K. Saleem, and S. Gul, “Enhancing oral solubility and permeability of edoxaban tosylate via development of self-microemulsifying drug delivery system,” Pharmaceutical Communications, vol. 2, no. 2, 2023.	2023
5	H. Afzaal, R. Altaf, U. Ilyas, S. U. Zaman, S. D. Abbas Hamdani, S. Khan, H. Zafar, M. M. Babar, and Y. Duan, “Virtual screening and drug repositioning of FDA-approved drugs from the zinc database to identify the potential htert inhibitors,” Frontiers in Pharmacology, vol. 13, p. 1048691, 2022.	2022
6	U. Ilyas, M. Asif, M. Wang, R. Altaf, H. Zafar, M. M. Faran Ashraf Baig, A. C. Paiva-Santos, and M. Abbas, “Nanostructured lipid carrier-based delivery of pioglitazone for treatment of type 2 diabetes,” Frontiers in Pharmacology, vol. 13, p. 934156, 2022.	2022
7	T. Huang, B. Nazir, R. Altaf, B. Zang, H. Zafar, A. C. Paiva-Santos, N. Niaz, M. Imran, Y. Duan, M. Abbas et al., “A meta-analysis of genome-wide gene expression differences identifies promising targets for type 2 diabetes mellitus,” Frontiers in Endocrinology, vol. 13, p. 985857, 2022.	2022
8	Y. Yao, M. Habib, H. F. Bajwa, A. Qureshi, R. Fareed, R. Altaf, U. Ilyas, Y. Duan, and M. Abbas, “Herbal therapies in gastrointestinal and hepatic disorders: An evidence-based clinical review,” Frontiers in Pharmacology, vol. 13, p. 962095, 2022.	2022
9	M. Muddassir, A. Batool, M. Alam, G. A. Miana, R. Altaf, S. Alghamdi, M. Almehmadi, O. Abdulaziz, A. A. Alsaiari, M. U. K. Sahibzada et al., “Evaluation of in vitro, in silico antidiabetic and antioxidant potential of bioactivity based isolated “pakistanine” from berberis baluchistanica,” Arabian Journal of Chemistry, vol. 15, no. 11, p. 104221, 2022.	2022
10	R. Altaf, S. S. Jadoon, S. A. Muhammad, U. Ilyas, and Y. Duan, “Recent advances in immune checkpoint inhibitors for non-small lung cancer treatment,” Frontiers in Oncology, vol. 12, p. 1014156, 2022.	2022
11	U. Ilyas, B. Nazir, R. Altaf, S. A. Muhammad, H. Zafar, A. C. Paiva-Santos, M. Abbas, and Y. Duan, “Investigation of anti-diabetic potential and molecular simulation studies of dihydropyrimidinone derivatives,” Frontiers in Endocrinology, vol. 13, p. 1022623, 2022.	2022
12	R. Altaf, H. Nadeem, U. Ilyas, J. Iqbal, R. Z. Paracha, H. Zafar, A. C. Paiva-Santos, M. Sulaiman, and F. Raza, “Cytotoxic evaluation, molecular docking, and 2D-QSAR studies of dihydropyrimidinone derivatives as potential anticancer agents,” Journal of Oncology, vol. 2022, no. 1, p. 7715689, 2022.	2022
13	R. Altaf, H. Nadeem, M. N. Iqbal, U. Ilyas, Z. Ashraf, M. Imran, and S. A. Muhammad, “Synthesis, biological evaluation, 2D-QSAR, and molecular simulation studies of dihydropyrimidinone derivatives as alkaline phosphatase inhibitors,” ACS Omega, vol. 7, no. 8, pp. 7139–7154, 2022.	2022
14	U. Ilyas, L. T. Alkury, S. Naaz, S. A. Muhammad, H. Nadeem, R. Altaf, S. U. Zaman, M. Faheem, I. Sajid, M. T. Cheema et al., “Cytotoxic evaluation and molecular docking studies of aminopyridine derivatives as potential anticancer agents,” Anti-Cancer Agents in Medicinal Chemistry, vol. 22, no. 14, pp. 2599–2606, 2022.	2022
15	M. Ijaz-Ul-Haq, S. Zaheer, R. Altaf, and U. Ilyas, “Ceftriaxone injectables: An in vitro evaluation of antimicrobial activity and comparative efficacy,” Journal of Pharmaceutical Research International, vol. 34, no. 44B, pp. 31–38, 2022.	2022
16	R. Altaf, H. Nadeem, M. M. Babar, U. Ilyas, and S. A. Muhammad, “Genome-scale meta-analysis of breast cancer datasets identifies promising targets for drug development,” Journal of Biological Research-Thessaloniki, vol. 28, pp. 1–15, 2021.	2021
17	U. Ilyas, S. Naz, R. Altaf, H. Nadeem, S. A. Muhammad, M. Faheem, M. I. Qadir et al., “Design, synthesis and biological evaluations of 2-aminothiazole scaffold containing amino acid moieties as anti-cancer agents,” Pakistan Journal of Pharmaceutical Sciences, vol. 34, 2021.	2021
18	U. Ilyas, S. U. Zaman, R. Altaf, H. Nadeem, and S. A. Muhammad, “Genome wide meta-analysis of cDNA datasets reveals new target gene signatures of colorectal cancer based on systems biology approach,” Journal of Biological Research-Thessaloniki, vol. 27, pp. 1–13, 2020.	2020
19	U. Rasheed, U. Ilyas, S. Zaman, S. Muhammad, H. Afzaal et al., “ADME/T prediction, molecular docking, and biological screening of 1, 2, 4-triazoles as potential antifungal agents,” J Appl Bioinforma Comput Biol 7, vol. 1, p. 2, 2018.	2018
20	S. Khattak, T. Ahmad, S. H. Aftab-Ullah, F. Naseer, F. Zenab, R. Altaf et al., “Evaluation of prescription errors at healthcare system in Khyber Pakhtunkhwa (KPK), Pakistan,” International Journal of Basic Medical Sciences and Pharmacy (IJBMSP), vol. 7, no. 1, 2017.	2017
21	S. Ishtiaq, U. Ilyas, S. Naz, R. Altaf, H. Afzaal, S. A. Muhammad, S. U. Zaman, M. Imran, F. Ali, F. Sohail et al., “Assessment of the risk factors of hypertension among adult & elderly group in twin cities of Pakistan,” J Pak Med Assoc, vol. 67, no. 11, pp. 1664–1669, 2017.	2017
22	U. Ilyas, R. Altaf, S. Aun Muhammad, M. I. Qadir, H. Nadeem, and S. Ahmed, “Computational drug designing of newly synthesized triazoles against potential targets of methicillin resistant Staphylococcus aureus,” Pakistan Journal of Pharmaceutical Sciences, vol. 30, no. 6, 2017.	2017

SR.	CONFERENCE PUBLICATIONS	YEAR
1	U. Ilyas, R. Altaf, S. A. Muhammad, M. I. Qadir, H. Nadeem, S. Ahmed, Report: “Computational drug designing of newly synthesized triazoles against potential targets of methicillin resistant Staphylococcus aureus”. Pak J Pharm Sci. 2017, vol. 30, no. 6, pp. 2271-2279.	2017

Our Team

Dr. Reem

PROFILE SUMMARY

Other Members